News Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Continue Reading Previous Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™Next Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program Related Stories News Hyper Bit Technologies Completes Acquisition of Dogecoin Mining Technologies News Miivo Engages Apaton Finance for Investor Awareness Services News Voghion Expands Sustainable Product Categories to Meet Growing European Demand News AITO Retains Top Position in Interbrand’s Luxury NEV Ranking in China for Second Consecutive Year News Metaguest.AI Announces Receipt of Shareholder Requisition News Parvis Signs Binding Share Purchase Agreement to Acquire Atlas One Digital Securities, Consolidating Canada’s Private Investment Market
